662 related articles for article (PubMed ID: 35820601)
1. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment.
Gao Q; Feng J; Liu W; Wen C; Wu Y; Liao Q; Zou L; Sui X; Xie T; Zhang J; Hu Y
Adv Drug Deliv Rev; 2022 Sep; 188():114445. PubMed ID: 35820601
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs.
Huang W; Chen L; Kang L; Jin M; Sun P; Xin X; Gao Z; Bae YH
Adv Drug Deliv Rev; 2017 Jun; 115():82-97. PubMed ID: 28624478
[TBL] [Abstract][Full Text] [Related]
3. Promising Nanomedicines of Shikonin for Cancer Therapy.
Yan C; Li Q; Sun Q; Yang L; Liu X; Zhao Y; Shi M; Li X; Luo K
Int J Nanomedicine; 2023; 18():1195-1218. PubMed ID: 36926681
[TBL] [Abstract][Full Text] [Related]
4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
5. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
6. Phytofabricated Nanoparticle Formulation for Cancer Treatment: A Comprehensive Review.
Verma M; Fatima S; Ansari IA
Curr Drug Metab; 2022; 23(10):818-826. PubMed ID: 35490313
[TBL] [Abstract][Full Text] [Related]
7. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy.
Li Q; Liu X; Yan C; Zhao B; Zhao Y; Yang L; Shi M; Yu H; Li X; Luo K
Small; 2023 Jun; 19(23):e2206211. PubMed ID: 36890780
[TBL] [Abstract][Full Text] [Related]
8. Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review.
Dombe S; Shirote P
Curr Drug Targets; 2021; 22(4):443-462. PubMed ID: 33045959
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in herbal combination nanomedicine for cancer: delivery technology and therapeutic outcomes.
Anwar DM; El-Sayed M; Reda A; Fang JY; Khattab SN; Elzoghby AO
Expert Opin Drug Deliv; 2021 Nov; 18(11):1609-1625. PubMed ID: 34254868
[No Abstract] [Full Text] [Related]
11. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
12. Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.
Fakhri S; Moradi SZ; Faraji F; Farhadi T; Hesami O; Iranpanah A; Webber K; Bishayee A
Cancer Metastasis Rev; 2023 Sep; 42(3):959-1020. PubMed ID: 37505336
[TBL] [Abstract][Full Text] [Related]
13. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
14. Anticancer nanomedicines harnessing tumor microenvironmental components.
Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
[TBL] [Abstract][Full Text] [Related]
15. Combination antitumor therapy with targeted dual-nanomedicines.
Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
[TBL] [Abstract][Full Text] [Related]
16. Micelles as potential drug delivery systems for colorectal cancer treatment.
Fatfat Z; Fatfat M; Gali-Muhtasib H
World J Gastroenterol; 2022 Jul; 28(25):2867-2880. PubMed ID: 35978871
[TBL] [Abstract][Full Text] [Related]
17. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
18. Phytochemical-Based Nanomedicine for Targeting Tumor Microenvironment and Inhibiting Cancer Chemoresistance: Recent Advances and Pharmacological Insights.
Sa P; Mohapatra P; Swain SS; Khuntia A; Sahoo SK
Mol Pharm; 2023 Nov; 20(11):5254-5277. PubMed ID: 37596986
[TBL] [Abstract][Full Text] [Related]
19. Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations.
Chan MM; Chen R; Fong D
Cancer Lett; 2018 Oct; 433():53-64. PubMed ID: 29960048
[TBL] [Abstract][Full Text] [Related]
20. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system.
Chen B; Dai W; Mei D; Liu T; Li S; He B; He B; Yuan L; Zhang H; Wang X; Zhang Q
J Control Release; 2016 Nov; 241():68-80. PubMed ID: 27641831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
